Tag: Liquid Biopsy

Grail’s Billion Dollar Bet for the Perfect Cancer Test

| June 11, 2017 | 1 Comment

Thought this was worth sharing from MIT Technology Review. After attending ASCO last week what I thought might happen a year or two again actually has. Pathologists no longer have to worry about stepping out from behind the paraffin curtain as many of us were fond of saying. Tissue is not the issue anymore. At […]

Continue Reading

The Future of Anatomic Pathology – 2 Possible Outcomes and More

| January 31, 2017 | 2 Comments

allthingspath.com had a recent interesting post on 2 possible outcomes for anatomic pathology at some point in the future of anatomic pathology.  One scenario is related to whole slide imaging and the other one is related to in vivo microscopy.  We are asked – Which one of these prevails? In my opinion, both.  There will […]

Continue Reading

Liquid Biopsies About to Get a Billion Dollar Boost

| January 18, 2017 | 0 Comments

Grail, a company that aims to use a blood test to spot cancer, has announced a massive round of funding for its experimental approach. A billion dollars sounds like a lot of money. But when your ambitions are as big as the cancer-detection startup Grail Bio’s are, it might not be enough. As CEO and […]

Continue Reading

Will Cancer Still Be a Surgical Disease in 2027?

| December 25, 2016 | 0 Comments

As we get ready to flip the calendars over to 2017, a year that seems almost made up from the time I was about 10 in 1980 thinking wasn’t even a real number. By now we were supposed to be flying around in our transport pods with flux capacitors, without roads, carrying light sabers perhaps […]

Continue Reading

IBM Jumps Into Liquid Biopsy Market

| August 8, 2016 | 0 Comments

If immunotherapy has the cancer community riveted on the treatment side, liquid biopsies are equally exciting on the diagnostics end. And IBM is bringing its research heft to bear on the world of liquid biopsy with an intent to build a lab-on-a-chip technology that can separate particles at the nanoscale. The ability to do that can […]

Continue Reading

FDA Approves First Liquid Biopsy Test for Use in Non-Small Cell Lung Cancer

| June 1, 2016 | 0 Comments

Exciting news today from FDA with news of approval of first liquid biopsy test for use in non-small cell lung cancer.  The cobas EGFR test is already approved for use in formalin-fixed paraffin-embedded (FFPE) tissue. This new use is intended for detection of these specific mutations in circulating-free tumor DNA (cfDNA) from plasma for first […]

Continue Reading

Visit Trovagene at ASCO 2016 – Booth 3014

I think that liquid biopsy, that is, using urine or peripheral blood samples will revolutionize cancer care and pathology over time.  Right now testing may be more limited with limited clinical trials but over time I think liquid biopsy will not only be used for drug response and monitoring during therapy but also for screening […]

Continue Reading

Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform

| February 23, 2016 | 0 Comments

Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, recently announced the availability of the ConcordiaT cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsyR platform. When coupled with Thermo Fisher Scientific’s Ion TorrentT next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell […]

Continue Reading

No Cell Left Behind

| January 31, 2016 | 1 Comment

Interesting article by Kathy Liszewski over at Genetic Engineering and Biotechnology News looking at circulating tumor cells (CTCs) incorporated with digital pathology. There is little doubt in my mind that technologies involving CTCs, liquid biopsy (see my thoughts from ASCO 2015) and digital pathology are going to converge.  The ability to identify individual cells and specific […]

Continue Reading

Cynvenio and ATGen Open Recruitment for New LiquidBiopsy Clinical Research Study in Triple Negative Breast Cancer

| January 8, 2016 | 0 Comments

New trial is open to patients who have completed standard treatments; Goal is to determine if cancer recurrences can be detected earlier and lead to improved targeted outcomes. Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients and ATGen Global, a Korea-based biotech company, recently announced the […]

Continue Reading

New Leadership, Multi-Million Dollar Cash Infusion to Drive WaveSense IVD Commercialization

| September 14, 2015 | 0 Comments

Irvine, CA (September 10, 2015) – WaveSense has named two veteran health care executives to top leadership positions and received a multi-million dollar capital investment to drive the company’s growth. WaveSense is the developer of the only FDA-registered in vitro diagnostic (IVD) devices for targeted cell isolation and enrichment. The sensitivity of this patented platform technology enables major […]

Continue Reading

Thoughts on ASCO 2015

| June 8, 2015 | 1 Comment

Had the opportunity to attend ASCO last week with a few goals in mind: Get updates on current trends in oncology management as oncologists are common clients of pathologists and laboratories. Spend some time in the exhibit area to see how personalized medicine is being marketed to oncologists. Assess what is happening in the genomics/proteomics […]

Continue Reading